Cumberland Pharmaceuticals (CPIX) said late Tuesday it will collaborate with Qureight to enhance the output of its Phase 2 trial evaluating the ifetroban drug candidate for idiopathic pulmonary fibrosis.
Under the collaboration, Cumberland will use Qureight's artificial intelligence-based image analytics tools to extract deeper insights into treatment efficacy and disease progression.
The Phase 2 trial includes 128 patients, both on existing antifibrotic therapies and those not receiving similar treatments. The primary endpoint focuses on change in forced vital capacity, the company said.
Both companies will attend the upcoming American Thoracic Society International Conference in San Francisco, where the trial study will be featured in the Clinical Trial Awareness section, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.